atrovent inhaler cfc-free 20 mcg/actuation pressurised inhalation solution
boehringer ingelheim limited - ipratropium bromide - pressurised inhalation, solution - ipratropium bromide 20 µg - drugs for obstructive airway diseases
atrovent 20micrograms/dose inhaler cfc free
boehringer ingelheim ltd - ipratropium bromide - pressurised inhalation - 20microgram/1dose
insuman infusat 100unitsml solution for injection 10ml vials
sanofi - insulin human - solution for injection - 100unit/1ml
insuman infusat 100unitsml solution for injection 3.15ml cartridges
sanofi - insulin human - solution for injection - 100unit/1ml
ptfe polymer oval pledgets - cardiovascular patch, synthetic
medtronic australasia pty ltd - 31744 - cardiovascular patch, synthetic - ptfe polymer oval pledgets are nonabsorbable, undyed fabrics composed of poly (tetrafluoroethylene). ptfe pledgets elicit a minimal acute inflammatory reaction in tissues, followed by gradual encapsulation of the fabric by fibrous connective tissue. ptfe pledgets are not absorbed, nor is any significant change in tensile strength retention known to occur in vivo. ptfe polymer oval pledgets are indicated for use as non-absorbable suture buttresses when there is a possibility of suture tearing through tissue. these pledgets are used in various surgical procedures such as vascular closure, septal repair, myocardial closure, valvular suturing and hepatic repair.
flixotide evohaler 125mcg
glaxosmithkline pharmaceutical sdn. bhd. - fluticasone propionate -
flixotide evohaler 50mcg
glaxosmithkline pharmaceutical sdn. bhd. - fluticasone propionate -
glytrin 400 micrograms per metered dose sublingual spray
ayrton saunders (ireland) limited - glyceryl trinitrate - sublingual spray, solution - 0.7%w/w percent weight/weight - organic nitrates; glyceryl trinitrate
xofigo
bayer israel ltd - radium-223 dichloride - solution for injection - radium-223 dichloride 1100 kbq/ml at reference date - radium (223 ra) dichloride - xofigo monotherapy or in combination with luteinising hormone releasing hormone (lhrh) analogue is indicated for the treatment of adult patients with metastatic castration-resistant prostate cancer (mcrpc), symptomatic bone metastases and no known visceral metastases, in progression after at least two prior lines of systemic therapy for advanced pc (other than lhrh analogues), or ineligible for any available systemic mcrpc treatment.
xofigo
bayer israel ltd - radium-223 dichloride - solution for injection - radium-223 dichloride 1100 kbq/ml at reference date - radium (223 ra) dichloride - xofigo monotherapy or in combination with luteinising hormone releasing hormone (lhrh) analogue is indicated for the treatment of adult patients with metastatic castration-resistant prostate cancer (mcrpc), symptomatic bone metastases and no known visceral metastases, in progression after at least two prior lines of systemic therapy for advanced pc (other than lhrh analogues), or ineligible for any available systemic mcrpc treatment.